OKYO Pharma Ltd ADR
Price & Volume
Stats
See more52W Range | $0.80-$1.90 |
Market Cap | $36.5M |
Shares Short | 216,782 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$3.5M |
Diluted EPS | -$0.57 |
News
See moreYahoo Finance • last year
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
Yahoo Finance • last year
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
Yahoo Finance • last year
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
Yahoo Finance • last year
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
About
CEO | Dr. Gary S. Jacob Ph.D. |
Address | 14/15 Conduit St, London, United Kingdom, W1S 2XJ |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 8 |
